XRCC1 deficiency influences the cytotoxicity and the genomic instability induced by Me-lex, a specific inducer of N3-methyladenine.
Me-lex is a sequence-specific alkylating agent synthesized to preferentially (>90%) generate N3-methyladenine (3-mA) in the minor groove of double-strand DNA, in A-T rich regions. In this paper we investigated the effect of XRCC1 deficiency in the processing of 3-mA adducts generated by Me-lex, through the molecular analysis of the Hprt mutations and the evaluation of cytogenetic end points such as sister chromatid exchanges (SCEs), micronuclei (MN) and nucleus fragmentation. EM-C11 cells, deficient in XRCC1 activity, showed a 2.5-fold higher sensitivity to the toxicity of Me-lex compared to the DNA repair proficient parental CHO-9 cells, but were not hyper mutable. The spontaneous mutation spectrum at the Hprt locus generated in EM-C11 cells revealed a high percentage of genomic deletions. After Me-lex treatment, the percentage of genomic deletions did not increase, but a class of mutations which appeared to target regulatory regions of the gene significantly increased (p=0.0277), suggesting that non-coding Hprt genomic sequences represent a strong target for the rare mutations induced by Me-lex. The number of SCEs per chromosome increased 3-fold above background in 50mucapital EM, Cyrillic Me-lex treated CHO-9 cells, while at higher Me-lex concentrations a sharp increase in the percentage of MN and fragmented nuclei was observed. In EM-C11 cells the background level of SCEs (0.939+/-0.182) was approximately 10-fold higher than in CHO-9 (0.129+/-0.027) and higher levels of multinucleated cells and MN were also found. In EM-C11, even low doses of Me-lex (25microM) led to a significant increase in genomic damage. These results indicate that XRCC1 deficiency can lead to genomic instability even in the absence of an exogenous genotoxic insult and low levels of Me-lex-induced lesions, i.e., 3-mA and/or a BER intermediate, can exacerbate this instability.
Russo
Debora
D
Department of Epidemiology and Prevention, National Cancer Research Institute, Genova, Italy.
Fronza
Gilberto
G
Ottaggio
Laura
L
Monti
Paola
P
Perfumo
Chiara
C
Inga
Alberto
A
Iyer
Prema
P
Gold
Barry
B
Menichini
Paola
P
D000225:Adenine / Q000031:analogs & derivatives / Q000378:metabolism; D000477:Alkylating Agents / Q000494:pharmacology*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004249:DNA Damage / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D042822:Genomic Instability / Q000235:genetics*; D009153:Mutagens / Q000494:pharmacology*; D009429:Netropsin / Q000031:analogs & derivatives* / Q000494:pharmacology; D017384:Sequence Deletion; D000076105:X-ray Repair Cross Complementing Protein 1
D000477:Alkylating Agents; D004268:DNA-Binding Proteins; D009153:Mutagens; D000076105:X-ray Repair Cross Complementing Protein 1; C110963:methyl lexitropsin; C025946:3-methyladenine; D009429:Netropsin; D000225:Adenine
Chem Res Toxicol. 1996 Apr-May;9(3):563-7
8728498
Chem Res Toxicol. 2006 Dec;19(12):1580-94
17173371
Mol Pharmacol. 2005 Feb;67(2):572-81
15548765
Mutat Res. 2010 Jan 5;683(1-2):50-6
19874831
J Cell Biochem. 2004 Feb 1;91(2):250-7
14743385
DNA Repair (Amst). 2008 Mar 1;7(3):431-8
18182332
J Biol Chem. 2002 Aug 9;277(32):28663-8
12042310
J Biol Chem. 1998 Feb 27;273(9):5412-8
9479003
Mutat Res. 2000 Feb 16;459(1):1-18
10677679
Nat Rev Cancer. 2005 Dec;5(12):943-55
16294218
Nature. 1974 Sep 13;251(5471):156-8
4138930
DNA Repair (Amst). 2007 Feb 4;6(2):254-64
17118717
Nucleic Acids Res. 2008 Apr;36(7):2152-62
18281311
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11845-50
18701715
DNA Repair (Amst). 2003 Sep 18;2(9):955-69
12967653
Mutat Res. 1998 Feb 26;398(1-2):83-92
9626968
Mutat Res. 1993 Aug;288(2):237-48
7688083
Mutat Res. 2007 Mar 1;616(1-2):11-23
17157333
Cytogenet Genome Res. 2004;104(1-4):77-86
15162018
Mutagenesis. 1992 Jul;7(4):265-9
1518409
Cell Death Differ. 2001 Aug;8(8):817-28
11526435
Mutat Res. 2000 Nov 20;455(1-2):81-95
11113469
Carcinogenesis. 1994 Oct;15(10):2281-5
7955067
Q Rev Biophys. 2009 Feb;42(1):41-81
19508739
J Biol Chem. 2005 Aug 26;280(34):30206-13
15987676
Mutat Res. 2003 Jan 10;534(1-2):65-75
12504755
EMBO J. 1984 Nov;3(11):2569-73
6239774
Mutat Res. 1994 Apr;323(4):159-65
7512685
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):612-20
17255284
Mutat Res. 1985 Jun-Jul;150(1-2):77-84
4000169
Biochemistry. 1993 Aug 10;32(31):7954-65
8394120
J Biol Chem. 1999 Jun 25;274(26):18327-34
10373436
Mutagenesis. 1994 Jan;9(1):67-72
8208132
Cancer Res. 1994 Jun 1;54(11):3001-6
8187089
EMBO J. 1996 Feb 15;15(4):945-52
8631315
Leukemia. 2000 Aug;14(8):1451-9
10942242
Mutat Res. 2009 Dec 1;671(1-2):58-66
19729030
Biochemistry. 2004 Dec 28;43(51):16505-14
15610045
Mutat Res. 1998 Mar;407(2):109-16
9637239
Biochemistry. 2001 Feb 13;40(6):1796-803
11327842
J Biol Chem. 2001 Feb 16;276(7):5044-51
11069916